ARTICLE | Company News
FDA extends Remodulin review
April 12, 2001 7:00 AM UTC
The FDA extended for up to 90 days the review period for United Therapeutics' Remodulin ( UT-15) prostacyclin analog to treat pulmonary arterial hypertension. United Therapeutics (UTHR) said the exten...